Abstract
Skeletal dysplosin often results in severe short stature. This has traditionally not been thought to respond to GH treatment. We here report the first year growth response to GH treatment of a group of children with achondro- or hypochondroplosia.
Inclusion criteria: Height < -2SD, age >4yrs and <10yrs for girls and <12yrs for boys. Only prepubertal children were included in the study and irrespective of endogenous GH levels. The GH dose was randomised to 0.1 or 0.2 IU/kgxday, 7 days a week (Norditropin, Novo Nordisk). After 12 months of treatment the following growth parameters were recorded. Data is given as mean (SEM).
Conclusion: 12 months of GH treatment gives a significant increase in growth velocity without worsening body disproportions in children with achondroplasia or hypochondroplasia. No major difference was seen between the GH doses 0.1 or 0.2 u/kg
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hagenäs, L., Ritzén, M., Eklöf, O. et al. FIRST YEAR RESPONSE OF GROWTH IN SHORT CHILDREN WITH ACHONDROPLASIA OR HYPOCHONDROPLASIA TREATED WITH GROWTH HORMONE (GO). Pediatr Res 33 (Suppl 5), S40 (1993). https://doi.org/10.1203/00006450-199305001-00220
Issue date:
DOI: https://doi.org/10.1203/00006450-199305001-00220
